|
gptkbp:instanceOf
|
gptkb:immunosuppressant
gptkb:antineoplastic_agent
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01AA01
|
|
gptkbp:blackBoxWarning
|
myelosuppression
bladder toxicity
secondary malignancies
|
|
gptkbp:brand
|
gptkb:Cytoxan
gptkb:Endoxan
gptkb:Procytox
|
|
gptkbp:CASNumber
|
50-18-0
|
|
gptkbp:chemicalFormula
|
C7H15Cl2N2O2P
|
|
gptkbp:contraindication
|
active infections
severe bone marrow suppression
hypersensitivity to cyclophosphamide
|
|
gptkbp:discoveredBy
|
gptkb:Arnold_Holtzman
gptkb:Norbert_Brock
|
|
gptkbp:discoveredIn
|
1958
|
|
gptkbp:excretion
|
kidneys
|
|
gptkbp:interactsWith
|
gptkb:warfarin
allopurinol
phenobarbital
live vaccines
|
|
gptkbp:KEGGID
|
D00210
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:antineoplastic_agent
DNA crosslinking
|
|
gptkbp:MedlinePlusID
|
a682080
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
261.1 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
2907
CHEMBL54
DB00531
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
hair loss
infertility
bone marrow suppression
increased risk of infection
hemorrhagic cystitis
|
|
gptkbp:UNII
|
8N3DW7272P
|
|
gptkbp:usedFor
|
gptkb:nephrotic_syndrome
gptkb:cancer
multiple sclerosis
autoimmune diseases
lupus
rheumatoid arthritis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:CTX
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cyclophosphamide
|